With increasing media interest in prostate cancer and the availability of data to patients from support groups and the Internet, the knowledge and use of alternative therapies by patients is becoming more common. The purpose of our study was to quantify patient awareness and use of alternative therapies for the prevention and treatment of prostate cancer in the UK. In May 2000, we performed a survey of men attending our urology outpatient clinic for prostate cancer evaluation or follow-up. All men diagnosed with and those at high risk (abnormal prostate specific antigen) for prostate cancer were eligible for the study. Each eligible patient was then sent an anonymous 25-item questionnaire to explore their knowledge and use of various alternative therapies for prostate cancer. Out of 195 patients who were sent the questionnaire, 168 responded, for a response rate of 86%. One hundred and sixty-four were analysed. Eight-two out of 164 (50%) were aware of alternative therapies for prevention/treatment of prostate cancer, the most common were tomatoes/tomato-based products and low-fat diet. There were 27 (16.5%) respondents taking alternative therapies for their prostate. Private patients were more aware (60.4% private vs 46.2% NHS) of complimentary therapies and were more likely to take them (27.9% private vs 12.4% NHS) than National Health Service patients. The majority of patients (60%) had not informed their GP or urologist. Fifteen therapies and 12 medication sources were recorded. Asked if doctors should discuss non-prescribed therapies, even if there is no proven benefit, 62% said 'yes' while 29% said 'no'. Alternative therapy use for prostate cancer is likely to increase. If we don't ask patients specifically whether they are taking them, patients are unlikely to tell us. Urologists and clinical oncologists treating men with prostate cancer need to be aware of alternative therapies and have some understanding of any benefit or harm, not only to be able to answer patient's questions and offer advice, but also to consider interactions with other treatments. Prostate Cancer and Prostatic Diseases (2001) 4, 235-241.
Introduction
Alternative or complementary medicine is the term given to treatments that may be used as adjuncts to conventional treatment and are not usually taught in medical schools. 1 Eisenberg and colleagues 2,3 demonstrated a 30% increase in the use of alternative therapies and a 47% increase in the total number of visits to alternative medicine practitioners in America between 1990 and 1997. In the UK, the use of complimentary and alternative therapies for the treatment and prevention of diseases in all branches of medicine is also becoming more popular. 4, 5 An ever growing spectrum of therapies has been implicated to be beneficial for treating and preventing prostate cancer, 6 -17 with a correspondingly wide range of potential side effects and interactions with conventional treatments. With the increasing drive to encourage men to be more assertive about their own health, the subject of prostate cancer continues to receive much media attention. The increase in use of the Internet has no doubt also contributed to this, with one recent UK study reporting more than 20% of urology patients using the Internet to obtain further information about their health. 18 As urologists, considered by the patient as 'the expert' we will be increasingly asked by patients to comment and advise on media and Internet articles they have read.
Although there are studies, which have looked at the prevalence and patterns of use of complimentary therapies among prostate cancer patients in countries such as America 19, 20 and Canada, 21 our report is the first to look at such data from the UK.
Materials and methods
In May 2000, we conducted a cross-sectional survey of men attending an NHS outpatient urology clinic and a private hospital urology clinic in Oxford for prostate cancer evaluation or follow-up. Eligible participants had to have biopsy proven adenocarcinoma of the prostate or have an abnormal prostate specific antigen (PSA greater than 4 ng/ml). Anybody who did not speak English, or was not aware that they had prostate cancer or a raised PSA was excluded from the study.
A 25-item self-administered, anonymous questionnaire about complimentary therapies (see Appendix 1) was posted first class with a return stamped addressed envelope and cover letter stating the goals of the project. Questionnaires with incomplete or inconsistent answers were excluded from the analysis. The questionnaire included items about patient age range, race, occupation and whether or not the patient had a higher degree (referring to any university qualification or equivalent as well as second degrees, ie a PhD). It also included an extensive survey of patient knowledge of 14 types of alternative medicine treatments, where they had learnt about them, and whether they had thought of using, or had actually used any of them. Those who had reported using some form of alternative therapy were then asked where they had purchased their non-prescribed medication, how long they had taken it for and an estimate of monthly cost. Patients were asked whether they had informed their GP and urologist they were taking an alternative therapy and if not, why not. They were also asked whether a doctor had ever asked or even recommended alternative medicine for the prevention or treatment of prostate cancer, and if they felt that doctors should discuss alternative medicines with patients, even if there is no proven benefit for their use in humans.
Results
One hundred and ninety-five questionnaires were posted and 168 were returned, giving a response rate of 86%. Four were returned incomplete and were therefore excluded from the analysis. The analysis was carried out on 164 completed questionnaires. Baseline characteristics of the 164 patient questionnaires, analysed, with respect to age and consultation status (ie whether seen as an NHS or private patient) are listed in Table 2 ). Four patients reported learning about alternative therapies from the Internet.
Patients reported 17 different alternative therapies that they were aware of in association in the prevention of prostate cancer. These are listed in Table 3 . The commonest therapies that patients reported knowing an association with in the prevention of prostate cancer were tomatoes or tomato-based foods (29.9%), low fat diet (25.6%), garlic (15.9%) and saw palmetto (12.8%). Thirty-nine out of the 164 patients (23.7%) had thought seriously about taking a non-prescribed/alternative medication for the prevention of prostate cancer. However only 11 out of 164 (6.7%) had ever been asked by a doctor in the urology clinic whether or not they were taking any non-prescribed/alternative medicine for their prostate. An even smaller number, nine out of 164 (5.5%) reported a doctor ever having recommended such therapies. Combining both groups (NHS and private patients) 27 out of the 164 (16%) patient questionnaires analysed reported using some form of alternative therapy for their prostate, either at the time of completing the questionnaire, or at some time in the past. Of these 27 cases 12 were private patients and 15 were NHS patients. As for patient awareness of alternative therapies, a greater proportion of private patients reported using them compared to NHS patients, 27.9 and 12.4%, respectively. Only two out of the 27 users reported trying other medicines because of dissatisfaction with what the doctor had prescribed.
Therapies used were vitamins A, B, C, E, selenium, zinc, betacarotene, saw palmetto, IP6, CQ10, essiac, green tea and pumpkin seeds. The herbal supplement PCSPES was used by one private patient. The numbers of patients reporting use of each therapy is detailed in Table 4 . The most frequently used ingredient was selenium (n ¼ 9) followed by vitamin C (n ¼ 7) and zinc (n ¼ 7).
Eighteen out of the 27 'users' were taking at least one alternative therapy, and nine out of 27 were taking more than three concurrently. Only four patients reported using high dose vitamin therapy alone. One patient reported using homeopathy and Chinese herbs. Five out of the 27 'users' did not specify the therapy they were taking. Table  5 shows the numbers of patients in each group who were taking a combination preparation. In addition, eight patients named a specific brand-name, which was a combination of several ingredients. For example Prostabrite (three), Formula 600, Men's Formula by Nature's Sunshine, Efaprost, Prostade 300 and Seronea-C. Of the 27 men taking alternative therapies, 16 out of 27 (59.2%) had not informed their GP or urologist. Reasons given for this were non-enquiry by the physician (11 patients), thinking the doctor would not approve (two patients) or that the doctor would not be interested, because the information was irrelevant (three patients). One patient did not inform the doctors, as he thought the doses of alternative therapies were so small in comparison to conventional therapies not to be of significance. Another reported that he was taking alternative therapies for such a short period of time, that he also thought informing his doctors was irrelevant.
Twelve different medication sources were listed by users (see Table 6 ). The commonest source reported was a UK chemist. Duration of use did not correlate with any specific alternative therapy. Among patients using complimentary therapies, 15 out of 27 (55%) had been doing so for 12 months or longer. Average monthly cost of alternative therapy was £11.04 (range £4.25 -£21.00) for the NHS patients and £16.88 (range £5.00 -£80.00) for the private patients. PCSPES was the therapy that was reported to have been the most costly.
Discussion
Our study suggests that a significant proportion of men with or at high risk of prostate cancer are aware of 19, 20 and Canadian studies, 21 (with prevalence rates ranging from 24.3 to 80%). This may be because prevalence rates are genuinely lower in the UK. However unlike the Canadian and American studies, we did not include religious practices and massage in our list of alternative therapies. It may also be that our figures are an underestimate of the actual prevalence, in view of the fact that our study was a cross-sectional survey. When questioning patients at a single point in time, the number admitting to using alternative therapies is much lower than if surveyed over a longer study period, for example 5 y. 22 Patients reported several reasons for taking alternative therapies. Two patients reported dissatisfaction with conventional treatments. One patient believed that alternative therapies were more effective and two patients thought they had a lower side effect profile than conventional medicines. One patient reported feeling rushed and confused by seeing a different doctor each time he came to the NHS clinic. Alternative practitioners probably do spend more time listening to patients, treating the whole person, rather than just treating symptoms. Other studies have reported patients saying they need to feel they are taking an active role in their own management, which may follow on from feelings of helplessness when told a diagnosis. 23 It is regrettable that we did not determine when 'users' started taking alternative therapies in relation to duration of diagnosis or stage of disease. Commonsense would suggest that patients with quite advanced disease or of long duration might be more aware than patients with a new diagnosis and it would certainly have been interesting to know this. Our study included 18 men with a raised PSA in whom prostate cancer had not yet been confirmed. Although in this study none of these 18 men reported using alternative therapies, it is worth considering that the man who is aware of prostate cancer sufficient to take an alternative therapy for prevention may be more motivated to seek a PSA test. Although we were able to determine what class of therapies the patient was taking [ie (a) no medication (b) conventional medication only (c) alternative medication only or (d) both] we were unable to conclude whether those using alternative therapies did so as a substitute for or, in addition to conventional treatment. Nevertheless, the fact that only two out of the 27 users reported trying other medicines, because of dissatisfaction with what the doctor had prescribed, implies that the majority of users are likely to take an alternative therapy in addition to, rather than as a substitute to conventional medicine. The higher rate of complimentary therapy use in private patients was expected given the increased level of 'awareness' among these men. They may have higher levels of education and income, and the fact that a greater proportion of the private patients have a higher degree, compared to NHS patients, supports the possibility that they may be better educated. Those who are better educated are known to be more proactive about their own health in general, particularly preventative measures. 24, 25 Kao et al 26 showed in a study of patients undergoing treatment for localised prostate carcinoma that those engaging in alternative therapy practices tended to have higher levels of education and income.
The most popular therapies that patients reported being aware of were tomatoes/tomato based products (29.9%) and low-fat diet (25.6%). It is difficult to explain why tomatoes were reported so frequently, as there are many other fruits and vegetables that have been implicated to be prostate cancer protective. Although the majority of patients are unlikely to be aware of the results of diet studies looking specifically at prostate cancer risk 27 -29 it is not surprising to us that low-fat diet was the second most popular form of alternative treatment that patients reported using. It has long been known that a low-fat diet is good for us in other respects, for example, heart disease prevention and weight control. In our study three patients commented that they were taking an alternative therapy to prevent other non-urological pathologies too.
The majority of men taking alternative medication were either taking one combination tablet (eg Formula 600), or multiple separate therapies concurrently, rather than a single ingredient. This complicates data interpretation, in that some patients were therefore taking an ingredient, which they may not have been aware of. Many herbal medicines have significant pharmacological activity and the majority can be bought over the counter without a prescription. Some have potentially serious side effects or interactions. For example, it has been reported that PCSPES causes significant thromboembolic disease (including pulmonary emboli) in 4.3% of patients, 30 shark cartilage can induce hepatitis, 31 green tea rich in vitamin K and herbal products with antiplatelet activity can interact with anticoagulant therapies, 32 -34 and there are needlestick hazards of acupuncture. 35 It is therefore a concern that in our study 60% of patients taking alternative therapies had not informed their GP or urologist. If we do not specifically question patients about alternative therapy use during a urological consultation, the majority of patients are unlikely to volunteer this information. Our results support figures reported by Ernst, 6 who found that the majority of cancer patients using alternative therapies did not inform their physicians. It has also been shown that doctors considerably underestimate the proportion of their patients who engage in complimentary practices. 28 In our study 62% of patients felt that doctors should discuss non-prescribed therapies, even if there is no proven benefit in humans. This may simply be because of increasing awareness and use of alternative therapies for prostate cancer, or because patients are becoming more proactive and demanding more information from doctors relevant to their condition.
Conclusions
In UK prostate cancer patients or those at high risk, half are aware and 16% use one or more complimentary therapies for their prostate. Prevalence rates are higher for private patients. These figures, as well as the number of different therapies used are likely to increase. Some of these therapies can be dangerous, either in their own right or because of adverse interactions with conventional treatments. The majority of patients do not inform their doctors they are taking such therapies, unless specifically asked about them. Urologists treating men with prostate cancer therefore have a duty to ask patients if they are using alternative therapies, and should also have some knowledge of them so they are in a better position to educate and advise patients. 
